Grigoris Gerotziafas: 3 ASH 2025 Poster Awards for Our Team!
Grigoris Gerotziafas, Director of the Cancer, Vessels, Biology, and Therapeutics (CaVITE) Research Department, Head of the CRSA at Sorbonne University, shared on LinkedIn:
”Three ASH 2025 poster awards for our team!
Proud to announce that three posters presented at the ASH 2025 Annual Meeting (Orlando, December 6–9, 2025) received awards
Abstract 1316: “Fibrin clot shields drive clonal selection of cancer cells: Procoagulant properties and proliferative survival of clot-embedded cancer cells. A novel model of tumor microenvironment remodeling.”
By Noelin Baskaran and Mohammed Baghdadi et al.
Abstract 1302: “Tissue factor bearing microparticles drive thromboinflammation and predict DIC and mortality in sepsis: Results from the ROADMAP-Sepsis study.”
Led by Patrick Van Dreden et al.
Abstract 2687: “Venous thromboembolism in multiple myeloma patients treated with BCMA-directed CAR T-cell therapy: A systematic review and meta-analysis.”
Led by Pedro Henrique Las Casas et al.
This success highlights the strength of our “Cancer Vessels, Biology and Therapeutics” (CaVITE) Research Team — a true dream team at the
Centre de Recherche Saint Antoine”
All from ASH25 featured in Hemostasis Today.
-
Dec 10, 2025, 17:22In the Fight for Hematology: Adetokunbo O’s Reflections from ASH25
-
Dec 10, 2025, 17:11Driving Innovation in Rare Blood Disorders: Jeff Schaffnit’s ASH 2025 Perspective
-
Dec 10, 2025, 16:37Arthur Allen – The New President-Elect of the Anticoagulation Forum Board of Directors
-
Dec 10, 2025, 16:29Matthew D Neal: An Oasis in the Platelet Desert?
-
Dec 10, 2025, 16:14Yashpal Singh Rawat: Fortis Memorial Research Institute Made Its Positive Mark at ASH
-
Dec 10, 2025, 14:57Elvira Grandone Announces the 1st ThrombUS+ Data Challenge
-
Dec 10, 2025, 14:18Love Preet Kalra on A Paradigm Shift in ICH
-
Dec 10, 2025, 13:37Aakanksha A: A Highlight of the Week Was Presenting Our ASH Poster
-
Dec 9, 2025, 23:37Thomas Reiser: Renew Your ISTH Membership for 2025